Tonix Pharma ( (TNXP) ) has provided an update.
Tonix Pharmaceuticals has unveiled promising data for its TNX-801 vaccine, showing it is less virulent in immune-compromised mice compared to 20th-century vaccinia vaccines. This breakthrough suggests TNX-801 could be an effective candidate in controlling mpox spread. Investors should note the company’s forward-looking statements about product development and potential growth, while being mindful of inherent market risks.
Find detailed analytics on TNXP stock on TipRanks’ Stock Analysis page.
